Amgen Sees Positive Results From Kyprolis Study

Amgen took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.



from WSJ.com: US Business http://ift.tt/1AtzLAm

via IFTTT